All news

Pfizer to stop selling Premarin hormone therapy in Canada after internal review

Reuters · · AI-summarised by FinFlash

Pfizer will stop selling its Premarin hormone replacement therapy in Canada after an internal review, Reuters reported. Pfizer Canada confirmed no further batches of Premarin vaginal cream will be supplied; the product has been in short supply since June. The company said the decision is not linked to safety, efficacy or quality and applies only to Canada. Demand for hormone therapy has risen since US regulators removed long-standing safety warnings in November 2025.

So What?

The exit is small for Pfizer's revenue but may tighten supply for rival hormone therapy makers such as Bayer and Sandoz in Canada; no broad market impact expected.

Read original source

PFE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.